Literature DB >> 30397056

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

James A Karlowsky1, Heather J Adam1, Melanie R Baxter1, Andrew J Denisuik1, Philippe R S Lagacé-Wiens1, Andrew J Walkty1, Sailaja Puttagunta2, Michael W Dunne2, George G Zhanel3.   

Abstract

The in vitro activity of sulopenem was assessed against a collection from 2014 to 2016 of 539 urinary isolates of Escherichia coli from Canadian patients by using CLSI-defined broth microdilution methodology. A concentration of sulopenem 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Escherichia colizzm321990; penem; sulopenem; urinary

Mesh：

Substances：

Year:  2018        PMID： 30397056      PMCID： PMC6325175          DOI： 10.1128/AAC.01832-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Antianaerobic activity of sulopenem compared to six other agents.

Authors:  Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 2.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

3.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

4.  Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.

Authors:  K Okamoto; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

Authors:  T Gootz; J Retsema; A Girard; E Hamanaka; M Anderson; S Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Authors:  Patricia J Simner; George G Zhanel; Johann Pitout; Franil Tailor; Melissa McCracken; Michael R Mulvey; Philippe R S Lagacé-Wiens; Heather J Adam; Daryl J Hoban
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03       Impact factor: 2.803

Review 7.  Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden.

Authors:  Betsy Foxman
Journal:  Infect Dis Clin North Am       Date:  2013-12-08       Impact factor: 5.982

8.  Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Patricia J Simner; Melanie R DeCorby; Heather J Adam; Andrew Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

9.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

Review 10.  Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-05-10       Impact factor: 2.471
View more
  4 in total

Review 1.  Critical analysis of antibacterial agents in clinical development.

Authors:  Ursula Theuretzbacher; Karen Bush; Stephan Harbarth; Mical Paul; John H Rex; Evelina Tacconelli; Guy E Thwaites
Journal:  Nat Rev Microbiol       Date:  2020-03-09       Impact factor: 60.633

Review 2.  Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Authors:  George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2022-03-16       Impact factor: 9.546

3.  Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.

Authors:  Robert E Trout; Allison Zulli; Eugen Mesaros; Randy W Jackson; Steven Boyd; Bin Liu; Jodie Hamrick; Denis Daigle; Cassandra L Chatwin; Kaitlyn John; Lisa McLaughlin; Susan M Cusick; William J Weiss; Mark E Pulse; Daniel C Pevear; Greg Moeck; Luigi Xerri; Christopher J Burns
Journal:  J Med Chem       Date:  2021-06-30       Impact factor: 7.446

4.  Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.

Authors:  Balaji Veeraraghavan; Yamuna Devi Bakthavatchalam; Rani Diana Sahni
Journal:  Infect Dis Ther       Date:  2021-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.